US Growth Hormone Use in the Idiopathic Short Stature Era: Trends in Insurer Payments and Patient Financial Burden
Open Access
- 28 August 2019
- journal article
- research article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 3 (11) , 2023-2031
Abstract
Purpose To investigate trends in prevalence and expenditures of growth hormone (GH) use by U.S. youth in the last 15 years, a period during which FDA approved GH treatment for idiopathic short stature (ISS) and insurers imposed greater barriers to GH treatment reimbursements. Methods Using 2001-2016 OptumInsight commercial claims data, we analyzed trends in claims of GH drugs among beneficiaries aged 0-18 years (n=38,857 beneficiaries receiving GH). Outcome measures included annual prevalence of GH claims, and annual total insurer and total patient payments for GH claims. t-tests tested for linear time trends in outcomes. Percentage of beneficiaries switching GH brands also was calculated. Results Number of members with GH claims per 10,000 beneficiaries under age 18 rose steadily from 5.1 in 2001 to 14.6 in 2016, without a dramatic change around 2003, the ISS approval date. Mean total GH expenditures decreased (-26% in constant dollars), as did the estimated insurance-paid amount (-28%). However, mean total patient spending increased by 163%. Beneficiaries switching GH brands in the year ranged 1.4-3.6% in 2001-2007 and 5.1-8.8% afterwards, with 25.6% switching in 2009 and 13.9% switching in 2015. Main conclusions The FDA ISS approval was not a watershed event in the steady increase in GH utilization by U.S. youth. Progressive restrictions on coverage and formulary preference coverage strategies appear to have succeeded in lowering total expenditures and insurer burden of GH treatment per beneficiary. However, those savings were not passed on to patients, who bore greater burdens financially and from brand switches.Keywords
Funding Information
- Children’s Hospital of Philadelphia (Pediatric Academic Enrichment Fund Award)
This publication has 14 references indexed in Scilit:
- Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I DeficiencyHormone Research in Paediatrics, 2016
- Gender Bias in U.S. Pediatric Growth Hormone TreatmentScientific Reports, 2015
- A Systematic Review of the Impact of Physicians’ Occupational Well-Being on the Quality of Patient CareInternational Journal of Behavioral Medicine, 2015
- Optum Labs: Building A Novel Node In The Learning Health Care SystemHealth Affairs, 2014
- Consequences of Brand Switches During the Course of Pediatric Growth Hormone TreatmentEndocrine Practice, 2012
- Patient Cost-Sharing and Healthcare Spending GrowthJournal of Economic Perspectives, 2011
- Gender of Pediatric Recombinant Human Growth Hormone Recipients in the United States and GloballyThe Journal of Clinical Endocrinology & Metabolism, 2008
- Health Plans’ Strategies For Managing Outpatient Specialty PharmaceuticalsHealth Affairs, 2006
- Utah Growth Study: Growth standards and the prevalence of growth hormone deficiencyThe Journal of Pediatrics, 1994
- Growth hormone treatment in the United States: Demographic and diagnostic features of 2331 childrenThe Journal of Pediatrics, 1990